drugset / Trial / NCT01122199

Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors

NCT01122199

Phase 1 Completed 27 enrolled Shadia Jalal Amgen · collabNovartis · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test the safety of the combination of two drugs called RAD001 and AMG479. This study will see what effects (good and bad) RAD001 and AMG479 have on cancer. This study will also find the highest doses of RAD001 and AMG479 that can be given without causing severe side effects.

Timeline

Start
2010-05-14
Primary completion
2015-01-19
Completion
2015-01-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule 5 mg Oral
Subject Ganitumab Monoclonal antibody 12 mg/kg Intravenous

Indications